We explored effects of a1-adrenoreceptor blockade with prazosin on the increased vascular smooth muscle cell (SMC) DNA synthesis induced by angiotensin II (Ang II) in rats. Ang II was infused with or without prazosin or its solvent. Observations were compared with those in rats receiving saline or solvent. In group A, Ang II was infused for 2 weeks by subcutaneously implanted osmotic minipumps at a rate of 35 ng/100 g per minute. Group B received Ang II together with the a1-adrenoreceptor antagonist prazosin (0.35 gg/100 g per minute). Group C received Ang II and 50% dimethyl sulfoxide (DMSO), the solvent of prazosin; group D received 50%S DMSO; and group E received 0.9%Yo NaCI (Ang II vehicle). All animals were infused with 5-bromo-2'-deoxyuridine for 2 weeks via separate minipumps to measure DNA synthesis. Ang II significantly increased the fraction of DNA synthesizing SMCs in the media of the thoracic aorta from 0.4+0.1 % (mean± SD) in group E (n=6) to 10.8±7.0% in group A (n=8). Addition of prazosin to Ang II reduced the labeling fraction of SMCs to 3.0+2 .2% (group B, n=9) . The remaining SMC DNA synthesis in the prazosin-treated group was probably due to the effects of the solvent of prazosin, i.e., 50% DMSO, since infusion of 50%o DMSO alone increased the labeling fraction to 4.1±+2.0%o (group D, n =6). Comparable results were obtained in the carotid artery. Both systolic blood pressures and medial cross-sectional areas increased during Ang II infusion, but these parameters were not altered by prazosin or DMSO. We conclude that cal-adrenoreceptors are, either indirectly or by parallel stimulation, involved in the Ang lI-induced increase of medial SMC DNA synthesis in the rat. Stimulation of al-adrenoreceptors rather than an elevated blood pressure stimulated vascular SMC DNA synthesis.
We explored effects of a1-adrenoreceptor blockade with prazosin on the increased vascular smooth muscle cell (SMC) DNA synthesis induced by angiotensin II (Ang II) in rats. Ang II was infused with or without prazosin or its solvent. Observations were compared with those in rats receiving saline or solvent. In group A, Ang II was infused for 2 weeks by subcutaneously implanted osmotic minipumps at a rate of 35 ng/100 g per minute. Group B received Ang II together with the a1-adrenoreceptor antagonist prazosin (0.35 gg/100 g per minute). Group C received Ang II and 50% dimethyl sulfoxide (DMSO), the solvent of prazosin; group D received 50%S DMSO; and group E received 0.9%Yo NaCI (Ang II vehicle). All animals were infused with 5-bromo-2'-deoxyuridine for 2 weeks via separate minipumps to measure DNA synthesis. Ang II significantly increased the fraction of DNA synthesizing SMCs in the media of the thoracic aorta from 0.4+0.1 % (mean± SD) in group E (n=6) to 10 .8±7.0% in group A (n=8). Addition of prazosin to Ang II reduced the labeling fraction of SMCs to 3.0+2.2% (group B, n=9). The remaining SMC DNA synthesis in the prazosin-treated group was probably due to the effects of the solvent of prazosin, i.e., 50% DMSO, since infusion of 50%o DMSO alone increased the labeling fraction to 4.1±+2.0%o (group D, n =6). Comparable results were obtained in the carotid artery. Both systolic blood pressures and medial cross-sectional areas increased during Ang II infusion, but these parameters were not altered by prazosin or DMSO. We conclude that cal-adrenoreceptors are, either indirectly or by parallel stimulation, involved in the Ang lI-induced increase of medial SMC DNA synthesis in the rat. Stimulation of al-adrenoreceptors rather than an elevated blood pressure stimulated vascular SMC DNA synthesis. (Circulation Research 1992;70:1122-1127) KEY WORDs * smooth muscle cell * DNA synthesis * angiotensin H * eta-adrenoreceptor T here is considerable interest in control mechanisms of accelerated smooth muscle cell (SMC) DNA synthesis as a critical event in the pathogenesis of hypertension and atherosclerosis.1-3 Although most attention has been devoted to polypeptide growth factors as initiators of this response, recent studies indicate that the variety of substances that may be involved in the regulation of vascular SMC DNA synthesis includes endogenous regulators of arterial blood pressure, such as angiotensin II (Ang II). [4] [5] [6] Evidence that Ang II increases vascular SMC DNA synthesis in vivo includes effects of inhibitors as well as agonists. The thoracic aorta of the two-kidney, one-clip Goldblatt hypertensive rat, an Ang II-dependent model of hypertension, shows an increase in the frequency of polyploid SMCs, suggesting that elevation of Ang II may cause SMC DNA synthesis.7 Inhibition of the formation of Ang II prevents the development of a neointima after balloon injury in the rat.5 A recent study from our laboratories shows that continuous infusion of Ang II stimulates DNA synthesis in both medial and neointimal vascular SMCs. 6 These in vivo studies obviously cannot distinguish between direct and indirect effects of the peptide. In vitro, Ang II stimulates SMC hypertrophy but not proliferation,8-10 suggesting that the in vivo effects of Ang II on SMC replication are indirect. Possible mediators in vivo include increased blood pressure and an increased activity of the sympathetic nervous system. This latter possibility is especially attractive since sympathetic nerves and catecholamines can influence the growth control of vascular SMCs both in vitro and in vivo,11-4 whereas Ang II is known to stimulate the activity of the sympathetic nervous system. This can be achieved through activation in the central nervous system, facilitation of peripheral adrenergic neurotransmission, inhibition of norepinephrine reuptake, and potentiation of postjunctional responses of SMCs to a,-adrenoreceptor stimulation. [15] [16] [17] [18] To test the hypothesis that SMC DNA synthesis induced by infusion of Ang II is mediated through stimulation of a1-adrenoreceptors, Ang II was infused together with the specific a1-adrenoreceptor antagonist prazosin in normal adult rats. DNA-synthesizing vascular SMCs were labeled by the concomitant infusion of the thymidine analogue 5-bromo-2'-deoxyuridine (BrdUrd). 19 The results indicate that the induction of vascular SMC DNA synthesis by Ang II is indeed dependent on a1-adrenoreceptor stimulation and independent of the rise in blood pressure.
Materials and Methods
Male adult Wistar-Kyoto rats (n=33; body weight, 300-350 g) obtained from local inbred strains (University of Limburg) were used. Food and tap water were provided ad libitum.
Rats were randomly assigned to one of five groups: group A (n=8) received Ang II; group B (n =9) received Ang II and prazosin-50% dimethyl sulfoxide (DMSO); group C (n=4) received Ang II and 50% DMSO; group D (n=6) received the solvent of prazosin, i.e., 50% DMSO in 0.9% NaCl; and group E (n=6) received 0.9% NaCl, the solvent of Ang II.
Blood Pressure Measurement
Systolic blood pressures were measured by the tailcuff plethysmograph method (Narco Biosystems, Houston, Tex.) on conscious, slightly restrained rats that were trained for the procedure for 7 days. Measurements were started 1 week before treatment and were performed three times a week. The mean of four measurements obtained in one session was used.
Drug Infusion Protocol
Ang II (groups A, B, and C) or 0.9% NaCl (groups D and E) were infused continuously for 2 weeks by osmotic minipumps (Alzet model 2001, Alza Corp., Palo Alto, Calif.) implanted subcutaneously between the shoulder blades under ether anesthesia. Rat Ang II (Sigma Chemical Co., St. Louis, Mo.) was dissolved in 0.9% NaCl (7.35 ,ug/,ul) and infused at a rate of 122.5 ng/min (35 ng/100 g per minute).
During the same surgical session, a second osmotic minipump (Alzet model 2m11) filled with prazosin dissolved in 50% DMSO (group B) or 50% DMSO (groups C and D) was implanted subcutaneously between the shoulder blades. Prazosin (Pfizer, Belgium) was dissolved in 50% DMSO (7.3 mg/ml) and infused at a rate of 1.23 ,tg/min (0.35 ,ug/100 g per minute).
Assessment of ax1-Adrenoreceptor Blockade by Prazosin
The degree of vascular a1-adrenoreceptor blockade was tested in a separate series of experiments by establishing the ED50 for phenylephrine in control and prazosin-treated Wistar-Kyoto rats. Prazosin, dissolved in 50% DMSO, was given via a subcutaneously implanted osmotic minipump (Alzet model 2m11) for 1 week at an infusion rate of 0.17 ,ug/100 g per minute. Control rats received an osmotic minipump (Alzet model 2m11) filled with 50% DMSO. On the day of the measurements, the rats were anesthetized with pento-implanted in the abdominal aorta via a femoral artery to measure blood pressure. A second PE-10 catheter was introduced in the abdominal vena cava via a femoral vein for phenylephrine infusions. The arterial catheter was connected to a pressure transducer (Statham). Signals were recorded on a polygraph (model 7D, Grass Instrument Co., Quincy, Mass.).
Phenylephrine was administered by continuous infusion. A dose-response curve was obtained with infusions ranging from 0.01 to 100 ,ug/kg per minute. Infusions were continued until maximal blood pressure responses were achieved and then increased in a stepwise manner. From the logarithmic dose-response curve, the ED5s was calculated as the dose resulting in 50% of the maximal response.
5-Bromo-2'-Deoxyuridine Labeling
BrdUrd (Serva, Heidelberg, FRG), a thymidine analogue that is incorporated into DNA-synthesizing cells, was given to all rats via separate subcutaneously implanted osmotic minipumps (30 mg/ml in 0.9% NaCl, Alzet model 2001) with an infusion rate of 0.5 ,ug/min (143 ng/100 g per minute). Infusion was started at the same time as drug infusion. Our own studies as well as information from the literature indicate that the data obtained with BrdUrd labeling correspond well with data on [3H]thymidine incorporation, as detected by autoradiography.20 -22 All infusions were continued for 2 weeks. The minipumps were implanted at day 0 and replaced after 1 week. Two weeks after the start of the infusions, each rat was killed in deep ether anesthesia, and the arterial system was perfusion-fixed for 5 minutes with 4% phosphate-buffered paraformaldehyde via a catheter placed in the abdominal aorta, after which the thoracic aorta and left carotid artery were excised.
Immunohistochemistry
Cross sections (4 gm) of the thoracic aorta and carotid artery were stained immunohistochemically for BrdUrd. BrdUrd-labeled nuclei were visualized using an indirect enzyme-labeled antibody technique. 23 Briefly, after rehydration of the sections, blocking of endogenous peroxidase, washing in phosphate-buffered saline (pH 7.4, three times for 5 minutes), and digestion in 0.1 mg/ml pepsin (Boehringer, Mannheim, FRG) in 0.1N HCl (30 minutes, 37°C), the sections were incubated in 2N HCI (30 minutes, 37°C) and washed in 0.1 M sodium tetraborate (pH 8.5). Incubation with a monoclonal anti-BrdUrd antibody (Eurodiagnostics, Apeldoorn, The Netherlands) was followed by incubation with peroxidase-conjugated rabbit anti-mouse immunoglobulin G (Dakopatts, Glostrup, Denmark) for 1 hour at room temperature. 3,3'-Diaminobenzidine was used as a chromogen. The sections were counterstained with hematoxylin. Control sections were incubated with an indifferent monoclonal antibody (Leu-2b).
After immunostaining, the cumulative labeling fraction (LF[%] = lOx BrdUrd positive cells per total number of cells) for medial SMCs was determined (three cross sections per rat) as an indicator of SMC DNA synthesis. Cross-sectional areas of the media were measured using a computerized morphometry system (Mibarbital (50 mg/kg i.p.), and a PE-10 catheter was croscience Inc, Seattle, Wash.). Systolic blood pressures increased more than 40 mm Hg within the first week of Ang II infusion and at-H---+s +
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The body weight of rats treated with Ang II (groups A *Significantly differenit from A, B, and C) was significantly reduced, whereas the body weight of the rats in the other groups did not change (data not shown).
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The LF of SMCs in the media of the thoracic aorta ANOVA was used for blood increased during Ang II infusion from 0.4+0.1% in the it. ANOVA was followed by 0.9% NaCI control group to 10.8±7.0% (Table 1) . Praare presented as mean-+-SD zosin significantly reduced the LF by more than 70% to cance was assumed atp<0.05.
3.0+2.2% (Table 1 ), but the LF in this group was still increased as compared with animals in the NaCI group. (Table 1) . Comparable data were obtained in the carotid artery ( Figure 2 , Table 1 ). Ang II infusion increased the carotid medial SMC LF to 8.3±4.9% versus 0.7±1.0% in the NaCl control group, whereas cotreatment with prazosin reduced the Ang Il-induced increase in the SMC LF to 4.7±6.0%. DMSO treatment during 2 weeks increased SMC DNA synthesis to 7.2+6.2%, which is different from the NaCI control group but not different from the Ang II-prazosin group. Ang II infused together with DMSO significantly increased the carotid artery LF to 11.5±4.4% (Table 1, group C).
Ang II infusion increased the cross-sectional area of the media of the thoracic aorta from 0.55±0.07 mm2 in the NaCl control group to 0.86±0.11 mm2 ( Table 2) . Infusion of prazosin did not affect this parameter: the cross-sectional area of the thoracic aorta in the Ang TI-prazosin group was similar to the cross-sectional area of the thoracic aorta in the Ang IT-treated group. Infusion of DMSO did not affect medial cross-sectional area.
Comparable effects of Ang II and Ang II-prazosin were found on the medial cross-sectional area of the carotid artery: a significant increase was seen from 0.13±0.01 mm2 in the control group to 0.19±0.03 mm2 in the Ang IT-treated group, whereas no effect of prazosin was observed (0.17±0.01 mm2, Table 2 ). Discussion The present study contains several distinct observations. First of all, the data confirm our previous results that continuous infusion of Ang II increases SMC DNA synthesis in the media of both the thoracic aorta and the carotid artery of the rat.6 Second, the stimulatory effect of Ang II on SMC DNA synthesis was markedly decreased by cotreatment with the a1-adrenoreceptor antagonist prazosin. A third interesting observation was the dissociation between the effects of a1-adrenoreceptor blockade on the Ang Il-induced increase in medial cross-sectional area and systolic blood pressure and the induction of arterial SMC DNA synthesis. Although the Ang Il-induced increase in DNA synthesis was almost completely prevented by prazosin, the drug was not effective in lowering the Ang IT-induced increase in systolic blood pressure or medial cross-sectional area. LFs in the media of the thoracic aorta and carotid artery of rats cotreated with prazosin were reduced by 50% as compared with levels in rats infused with Ang II. The failure of the antagonist to lower replication rates to control levels could represent a dose-response problem, since only one dose of prazosin was used. However, this is unlikely, since prazosin caused an approximately 160-fold shift in the dose-response curve of phenylephrine, indicating effective blockade of the a1-adrenoreceptor. It is also possible that, although prazosin was completely effective, the inhibitory effects of prazosin were masked by the unexplained mitogenic effects of DMSO, the vehicle that was used for the continuous delivery of prazosin via osmotic minipumps. Another possibility is that prazosin blocked not only the aladrenoreceptor but also the a2-adrenoreceptor. Prazosin, like other a1-adrenoreceptor antagonists, has the ability to block the a2-adrenoreceptor. It has been shown, however, that prazosin is a highly selective a1-adrenoreceptor antagonist with a more than 250 times higher affinity for the a1-adrenoreceptor than for the a2-adrenoreceptor,25 which makes possible a2-adrenoreceptor-blocking effects of prazosin in the current study very unlikely.
Thus, the data suggest that the in vivo effects of Ang II infusion on SMC DNA synthesis are indirect and mediated via stimulation of the a1-adrenoreceptor. The sympathetic nervous system and especially a1-adrenoreceptor-mediated activity are known to play a role in vascular growth control, but the effects are complex and seem to be age dependent. Whereas sympathectomy greatly decreases DNA synthesis in the central ear artery of growing rabbits11 and attenuates the hypertrophic response of cerebral arteries in young spontaneously hypertensive rats,26 the opposite occurs in vessels of adult animals.27 Gene expression studies suggest a possible mechanism for growth stimulation by Ang II requiring a1-adrenoreceptor-mediated activity. We have shown that the a1-adrenergic agonist phenylephrine can directly stimulate vascular smooth muscle to transcribe the mRNA of the platelet-derived growth factor A chain gene, a possible endogenous growth factor.28 In vitro autocrine studies with anti-plateletderived growth factor antibodies suggest that expression of platelet-derived growth factor may be necessary for growth stimulatory effects of interleukin-1, transforming growth factor-fl, and Ang II on SMCs.2930 Interest-Circulation Research Vol 70, No 6 June 1992 ingly, a1-adrenoreceptor blockade with prazosin or urapidil prevents the development of a neointima after balloon injury. [31] [32] [33] Although the data presented in this study show the involvement of the a,-adrenoreceptor in the induction of vascular SMC DNA synthesis by Ang II in vivo, the exact mechanism of interaction remains unclear. Ang II enhances sympathetic activity both centrally and peripherally. Since the aorta of an adult rat has a very limited sympathetic innervation,34 interactions at the central level are unlikely to be important, although central stimulation of the adrenal medulla to release catecholamines in the plasma cannot be excluded. At the level of the peripheral sympathetic nervous system, Ang II stimulates release of norepinephrine from adrenergic varicosities at the nerve terminal via stimulation of presynaptic Ang II receptors, inhibits the reuptake of norepinephrine, and increases postjunctional responses of SMCs to norepinephrine-mediated a1adrenergic stimulation. [15] [16] [17] [18] Assuming that peripheral modulation of a1-adrenergic activity by Ang II is important, this may occur via serial or parallel stimulation. Serial stimulation implies that stimulation of a1-adrenoreceptor-mediated activity is a prerequisite for the stimulatory effects of Ang II on vascular SMC DNA synthesis. This would indicate that the a1-adrenoreceptor and not Ang II is the control molecule. The parallel stimulation hypothesis implies that both systems are important in the control of SMC DNA synthesis and may act independently. Our earlier observation that a single injection of the a,-adrenergic agonist phenylephrine did not increase vascular SMC DNA synthesis27 does not help to discriminate between the two hypotheses, since it only indicates that a brief increase in plasma levels of phenylephrine is apparently not enough to stimulate SMC DNA synthesis. More experiments, like a continuous infusion of phenylephrine, are needed to elucidate the exact mechanism involved. Prazosin dissociated the response of Ang II on SMC DNA synthesis from its hypertrophic response. Whereas the drug significantly inhibited the increase in SMC DNA synthesis induced by Ang II, it did not affect the Ang lI-induced increase in systolic blood pressure and medial cross-sectional area.
Other authors have reported that medial hypertrophy is controlled by increases in blood pressure but that other factors may be important in the control of vascular SMC number. For instance, Owens and Reidy35 found that antihypertensive treatment with a combination of reserpine, hydralazine, and chlorothiazide prevented SMC hypertrophy but not an increase in cell number in the thoracic aorta of adult spontaneously hypertensive rats. Owens36 described that the effect of the angiotensin I converting enzyme inhibitor captopril on medial hypertrophy and the frequency of SMC polyploidy was over and above that predicted by its blood pressure-lowering effects and suggested a role of Ang II in the control of vascular growth. In agreement with this is the increase in SMC DNA synthesis in vessel segments protected from the blood pressure rise during aortic coarctation, an Ang II-dependent model of hypertension. 37 Recent in vivo experiments from Griffin et a138 extend the concept that Ang II may have hypertrophic effects II infusion also stimulates hypertrophy of the rat superior mesenteric artery but that addition of hydralazine to Ang II to prevent the blood pressure rise during Ang II infusion had no effect on mesenteric arterial hypertrophy. One important difference between the study presented here and the Griffin study is the vessel examined. Heterogeneity in growth response along the vascular tree has been described before. For instance, the cell number of mesenteric resistance arteries is increased in spontaneously hypertensive rats as compared with Wistar-Kyoto control rats, whereas no differences are found in larger arteries such as the thoracic aorta.39 It is also known that DNA synthesis in the arterial smooth muscle of young spontaneously hypertensive rats is not uniformly distributed. Although it is increased in the smooth muscle of large arteries, no differences between spontaneously hypertensive rats and age-matched Wistar-Kyoto rats were found in small resistance-sized arteries.40 The extension of our data to small vessels will therefore require a separate study.
Finally, these data may have important clinical consequences. Angiotensin converting enzyme inhibitors have been shown to be effective in reducing neointima formation after balloon injury in animals5 and are now being tested for their efficacy in preventing restenosis in humans. The recent studies of O'Malley et al32 and Fingerle et al33 have shown that specific a1-adrenoreceptor antagonists are as effective as angiotensin converting enzyme inhibitors in preventing neointima formation, and the data presented in the present study focus our attention on the role of the a,-adrenoreceptor in vascular SMC control in vivo. The data presented here suggest that the stimulatory effects of Ang II on SMC DNA synthesis are not direct but mediated via the a1-adrenoreceptor. By extension, it seems reasonable to assume that the inhibitory effects of angiotensin converting enzyme inhibition on neointima formation are also indirect and mediated via the a1-adrenergic receptor, which would make a1-adrenoreceptor antagonists the drugs of first choice for a rational therapy of restenosis.
